PT-141
FDA ApprovedAlso known as: Bremelanotide, Vyleesi
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. Acts centrally rather than on vascular mechanisms. Phase 3 RECONNECT trials demonstrated efficacy.
Research Statistics
FDA-approved (Vyleesi) melanocortin receptor agonist with 18 human studies; MC4R CNS pathway for sexual function is well-characterized, though clinical trials were predominantly US-based.
Research Dossier
Overview
What is PT-141 and what does the research say?
Mechanism of Action
PT-141 (bremelanotide) is an FDA-approved melanocortin receptor agonist that works centrally in the brain rather than through peripheral vasodilation. It is the first approved treatment that directly increases sexual desire.
How It Works (Simplified)
PT-141 acts through central nervous system pathways to enhance sexual desire:
Crosses the blood-brain barrier and binds MC4R in the hypothalamus, triggering dopamine release in sexual motivation circuits.
Unlike Viagra, PT-141 increases sexual desire itself rather than just physical response - it generates the “wanting” through dopaminergic activation.
MC4R activation also triggers spinal cord pathways that produce genital arousal responses independent of local blood flow mechanisms.
Effects begin 30-60 minutes after injection and peak within 1-4 hours. Short 2.7-hour half-life means effects are time-limited.
Scientific Pathways
MC4R Central Pathway (Sexual Desire)
PT-141 → Crosses BBB → MC4R in mPOA of hypothalamus → Dopamine release
↓
Increased sexual desire
Oxytocin pathway activationSpinal Cord Pathway (Arousal Response)
MC4R activation → Spinal cord pro-erectile signaling → Genital arousal responseKey Research: Kingsberg SA et al. (2019) Phase 3 RECONNECT trials demonstrated significant improvement in FSFI-D and FSDS-DAO scores in premenopausal women with HSDD. PMID:31599840
Important Limitations
- FDA-approved only for premenopausal women with HSDD
- Not approved for male erectile dysfunction despite early trials
- High nausea incidence (40%) limits tolerability
- Transient blood pressure increases require monitoring
- Use limited to 8 doses per month due to cardiovascular effects
- Contraindicated with uncontrolled hypertension or cardiovascular disease
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Based on clinical trials: Sexual desire effects begin 30-60 minutes after subcutaneous injection. This is the onset window observed in RECONNECT and REVEAL Phase 3 trials.
Peak effects typically occur within 1-4 hours of administration. Studies showed increased desire and arousal during this window. Nausea (40%) peaks and typically resolves within this period.
Effects may persist for 4-12 hours in some individuals. Duration is variable. The relatively short half-life means effects are time-limited compared to longer-acting therapies.
Effects generally resolve within 24 hours. PT-141 is used on an as-needed basis (at least 45 minutes before anticipated activity), not daily. Do not use more than once in 24 hours.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate PT-141 product quality
Good Signs (6 indicators)
Warning Signs (4 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining PT-141 with other peptides. Based on published research and mechanistic considerations.
BPC-157
CompatibleDifferent mechanisms with no known interaction. BPC-157's gastroprotective effects may theoretically help with PT-141's nausea, though this is speculative.
Thymosin-Alpha-1
CompatibleNon-overlapping mechanisms (immune modulation vs melanocortin signaling). No known contraindications.
Semaglutide
CautionBoth can cause nausea. PT-141 commonly causes nausea (40% incidence). GI adverse events may be additive. Monitor tolerability.
Tirzepatide
CautionSimilar caution as semaglutide. Both affect GI function and can cause nausea. Monitor for additive GI effects.
Melanotan-II
AvoidBoth are melanocortin receptor agonists with overlapping activity. PT-141 is derived from Melanotan II. Combining would provide redundant stimulation with increased adverse event risk.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare PT-141
PT-141 Calculators
Related Peptides
CJC-1295
DAC:GRF, Modified GRF 1-29, Tetrasubstituted GRF
A synthetic analog of growth hormone-releasing hormone (GHRH) with extended half-life. Limited clinical development; not approved for any indication.
Follistatin
FST, FS-344, FS-315 +1 more
An endogenous glycoprotein that inhibits myostatin and activin signaling, potentially allowing muscle growth beyond genetic limits. Gene therapy trials for muscular dystrophy show promise, but injectable peptide forms remain unapproved and understudied in humans.
GHRP-2
Growth Hormone Releasing Peptide-2, Pralmorelin, KP-102
A synthetic hexapeptide GH secretagogue with the strongest GH-releasing potency in its class. More potent than GHRP-6 with different side effect profile: less appetite stimulation but greater cortisol and prolactin elevation. Approved in Japan as Pralmorelin for GH deficiency diagnosis. Extensively studied in human pharmacology with robust clinical data.
GHRP-6
Growth Hormone Releasing Peptide-6, SKF-110679, Growth Hormone-Releasing Hexapeptide
A first-generation growth hormone secretagogue that stimulates GH release through the ghrelin receptor. Less selective than newer alternatives with effects on cortisol and prolactin. Historically significant as the peptide that led to ghrelin discovery. Cuban CIGB leads global cytoprotective research. Not approved for any indication.
Human Chorionic Gonadotropin (hCG)
hCG, Choriogonadotropin, Pregnyl +5 more
A glycoprotein hormone FDA-approved for ovulation induction, cryptorchidism, and hypogonadotropic hypogonadism. Functions as an LH receptor agonist with over 50 years of clinical use in reproductive medicine. Gold standard trigger for assisted reproductive technology.
Hexarelin
Examorelin, HEX, Growth Hormone Releasing Hexapeptide +2 more
The most potent synthetic GHRP (Growth Hormone Releasing Peptide), a hexapeptide that strongly stimulates GH release via the ghrelin receptor. Notable for cardioprotective effects independent of GH release. Development discontinued due to rapid desensitization with repeated dosing. Italian research leads global investigation.